Dr. Flinn on CAR T-Cell Therapy in Non-Hodgkin Lymphoma

Ian Flinn, MD
Published: Tuesday, Jul 10, 2018



Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma (NHL).

At the 2018 European Hematology Association Congress, updates were presented on the ZUMA-1 trial. The ZUMA-1 trial examined the use of the anti-CD19 CAR T-cell therapy axicabtagene ciloleucel (KTE-C19; axi-cel) in patients with refractory aggressive NHL. Results were previously published in the New England Journal of Medicine. Axi-cel demonstrated an objective response rate of 82% and a complete response rate of 54% in patients with NHL. Updated results show long-term responses, states Flinn.

Flinn says that the durability of remission was of particular interest, as the fall-off for response typically occurs within the first 3 months of treatment. If patients achieve a complete remission or a partial remission and keep that remission for 3 months, they are likely to maintain that response, explains Flinn.
SELECTED
LANGUAGE


Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma (NHL).

At the 2018 European Hematology Association Congress, updates were presented on the ZUMA-1 trial. The ZUMA-1 trial examined the use of the anti-CD19 CAR T-cell therapy axicabtagene ciloleucel (KTE-C19; axi-cel) in patients with refractory aggressive NHL. Results were previously published in the New England Journal of Medicine. Axi-cel demonstrated an objective response rate of 82% and a complete response rate of 54% in patients with NHL. Updated results show long-term responses, states Flinn.

Flinn says that the durability of remission was of particular interest, as the fall-off for response typically occurs within the first 3 months of treatment. If patients achieve a complete remission or a partial remission and keep that remission for 3 months, they are likely to maintain that response, explains Flinn.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x